<DOC>
	<DOC>NCT01389310</DOC>
	<brief_summary>The purpose of this study is to monitor adverse events in HIV-infected children &lt;18 years old who are exposed to Atazanavir in a real-world setting in Europe.</brief_summary>
	<brief_title>Post-marketing Safety Surveillance Program in Human Immunodeficiency Virus (HIV)-Infected Children Exposed to Atazanavir in Europe</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<criteria>HIVinfected children participating in individual prospective paediatric HIV cohorts Receive Atazanavir treatment during 01JAN2011 to 30DEC2013 Age &lt;18 years old on the date starting an Atazanavircontaining regimen Have a minimum of 3 months of followup</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>